4743.TWO
Oneness Biotech Co., Ltd. [4743.TWO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
4743.TWO Stock Summary
Top 10 Correlated ETFs
4743.TWO
Top 10 Correlated Stocks
4743.TWO
In the News
4743.TWO Financial details
Company Rating
Buy
Market Cap
93.62B
Income
-305.52M
Revenue
1.07B
Book val./share
37.33
Cash/share
21
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
09 Aug 2023
P/E
-297.48
Forward P/E
-
PEG
107.09
P/S
85.49
P/B
6.25
P/C
11.12
P/FCF
-88.78
Quick Ratio
40.96
Current Ratio
42.03
Debt / Equity
0.05
LT Debt / Equity
0.02
-
-
EPS (TTM)
-0.78
EPS next Y
-
EPS next Q
-
EPS this Y
-187.96%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
124.09%
Revenue Q/Q
50.16%
EPS Q/Q
-58.68%
-
-
-
-
SMA20
-3.32%
SMA50
-10.04%
SMA100
-7.54%
Inst Own
-
Inst Trans
-
ROA
-2%
ROE
-2%
ROC
-0.01%
Gross Margin
79%
Oper. Margin
-19%
Profit Margin
-29%
Payout
-
Shs Outstand
390.91M
Shs Float
0
-
-
-
-
Target Price
-
52W Range
155.5-309.5
52W High
-24.43%
52W Low
+50.65%
RSI
50
Rel Volume
0.52
Avg Volume
4.44M
Volume
2.3M
Perf Week
4.71%
Perf Month
-2.51%
Perf Quarter
-
Perf Half Y
-21.38%
-
-
-
-
Beta
1.68835
-
-
Volatility
4.43%, 8.24%
Prev Close
-2.71%
Price
233.5
Change
-3.11%
4743.TWO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.1 | 0.05 | 0.12 | 0.17 | 2.8 | |
| Net income per share | -1.2 | -1.28 | -0.71 | -1.08 | 0.95 | |
| Operating cash flow per share | -0.03 | -0.85 | 0.44 | -0.76 | -2.32 | |
| Free cash flow per share | -0.88 | -1.04 | 0.01 | -1.02 | -2.55 | |
| Cash per share | 3.21 | 6.32 | 23.31 | 20.48 | 21.15 | |
| Book value per share | 10.37 | 25.19 | 38.2 | 36.77 | 38.42 | |
| Tangible book value per share | 11.06 | 15.56 | 31.38 | 30.46 | 33.59 | |
| Share holders equity per share | 10.37 | 25.19 | 38.2 | 36.77 | 38.42 | |
| Interest debt per share | 0 | 1.33 | 0.86 | 0.76 | 0.7 | |
| Market cap | 5.21B | 7.38B | 86B | 109.59B | 93.41B | |
| Enterprise value | 5.06B | 7.55B | 86.09B | 109.54B | 88.01B | |
| P/E ratio | -22.12 | -22.92 | -341.72 | -265.47 | 259.48 | |
| Price to sales ratio | 276.15 | 547.96 | 2.07K | 1.67K | 87.66 | |
| POCF ratio | -1.02K | -34.62 | 543.85 | -379.35 | -106.02 | |
| PFCF ratio | -30.21 | -28.34 | 17.67K | -281.59 | -96.28 | |
| P/B Ratio | 2.57 | 1.17 | 6.31 | 7.82 | 6.39 | |
| PTB ratio | 2.57 | 1.17 | 6.31 | 7.82 | 6.39 | |
| EV to sales | 268.16 | 559.99 | 2.07K | 1.67K | 82.6 | |
| Enterprise value over EBITDA | -22.59 | -29.72 | -1.65K | -565.48 | 92.56 | |
| EV to operating cash flow | -987 | -35.38 | 544.39 | -379.18 | -99.9 | |
| EV to free cash flow | -29.33 | -28.96 | 17.69K | -281.47 | -90.72 | |
| Earnings yield | -0.05 | -0.04 | 0 | 0 | 0 | |
| Free cash flow yield | -0.03 | -0.04 | 0 | 0 | -0.01 | |
| Debt to equity | 0.08 | 0.08 | 0.12 | 0.12 | 0.05 | |
| Debt to assets | 0.07 | 0.07 | 0.11 | 0.1 | 0.04 | |
| Net debt to EBITDA | 0.67 | -0.64 | -1.64 | 0.25 | -5.67 | |
| Current ratio | 31.83 | 23.5 | 58.15 | 51.21 | 39.47 | |
| Interest coverage | -22.03K | -51.14 | -47.27 | -79.83 | 99.29 | |
| Income quality | 0.02 | 0.65 | -0.63 | 0.73 | -1.95 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 2.41 | 5.11 | 2.57 | 1.43 | 0.11 | |
| Research and developement to revenue | 5.01 | 17.71 | 14.16 | 12.26 | 0.86 | |
| Intangibles to total assets | 0 | 0.37 | 0.17 | 0.16 | 0.13 | |
| Capex to operating cash flow | 32.65 | 0.22 | -0.97 | 0.35 | 0.1 | |
| Capex to revenue | -8.87 | -3.51 | -3.68 | -1.53 | -0.08 | |
| Capex to depreciation | -14.36 | -0.71 | -0.8 | -0.51 | -0.18 | |
| Stock based compensation to revenue | 0.22 | 1.66 | 0.77 | 0.33 | 0.02 | |
| Graham number | 16.75 | 26.97 | 24.62 | 29.93 | 28.6 | |
| ROIC | -0.06 | -0.05 | -0.02 | -0.03 | 0.08 | |
| Return on tangible assets | -0.1 | -0.07 | -0.02 | -0.03 | 0.03 | |
| Graham Net | 2.47 | 4.35 | 18.83 | 16.3 | 19.46 | |
| Working capital | 721.76M | 1.62B | 8.78B | 7.89B | 8.02B | |
| Tangible asset value | 2.17B | 3.91B | 11.2B | 11.61B | 12.78B | |
| Net current asset value | 575.53M | 1.17B | 7.31B | 6.41B | 7.53B | |
| Invested capital | 0 | 0.05 | 0.02 | 0.02 | 0.02 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 259K | 377.5K | 24.37M | 25.09M | 1.58M | |
| Average inventory | 45.55M | 49.36M | 52.75M | 77.39M | 105.83M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 15.98 | 6.61 | 1.62K | 30.72 | 2.33 | |
| Days of inventory on hand | 1.8K | 1.04K | 1.92K | 1.72K | 188.2 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 22.84 | 55.2 | 0.22 | 11.88 | 156.63 | |
| Inventory turnover | 0.2 | 0.35 | 0.19 | 0.21 | 1.94 | |
| ROE | -0.12 | -0.05 | -0.02 | -0.03 | 0.02 | |
| Capex per share | -0.85 | -0.19 | -0.43 | -0.26 | -0.23 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.05 | 2.61 | 0.04 | 0.04 | 0.06 | |
| Net income per share | 1.01 | 0.87 | 0.71 | -1.67 | -0.69 | |
| Operating cash flow per share | -0.34 | -0.51 | -0.45 | -0.98 | -0.5 | |
| Free cash flow per share | -0.4 | -0.56 | -0.46 | -1.08 | -0.55 | |
| Cash per share | 19.84 | 19.5 | 21.8 | 20.73 | 21 | |
| Book value per share | 36.77 | 36.88 | 39.59 | 37.65 | 37.33 | |
| Tangible book value per share | 30.59 | 31.33 | 34.64 | 32.92 | 33.29 | |
| Share holders equity per share | 36.77 | 36.88 | 39.59 | 37.65 | 37.33 | |
| Interest debt per share | 0.72 | 0.68 | 0.68 | 0.68 | 0.67 | |
| Market cap | 82.81B | 68.28B | 98.03B | 95.31B | 103.93B | |
| Enterprise value | 82.84B | 68.38B | 97.69B | 89.92B | 103.33B | |
| P/E ratio | 53.28 | 50.43 | 88.91 | -36.64 | -96.45 | |
| Price to sales ratio | 4.12K | 67.15 | 7.08K | 6.45K | 4.68K | |
| POCF ratio | -634.36 | -345.16 | -563.27 | -251.74 | -537.01 | |
| PFCF ratio | -532.5 | -312.52 | -550.39 | -227.97 | -486.95 | |
| P/B Ratio | 5.83 | 4.76 | 6.38 | 6.52 | 7.15 | |
| PTB ratio | 5.83 | 4.76 | 6.38 | 6.52 | 7.15 | |
| EV to sales | 4.12K | 67.25 | 7.05K | 6.09K | 4.66K | |
| Enterprise value over EBITDA | 188.27 | 103.58 | 254.23 | -168.52 | -659.77 | |
| EV to operating cash flow | -634.59 | -345.66 | -561.35 | -237.5 | -533.93 | |
| EV to free cash flow | -532.69 | -312.97 | -548.52 | -215.07 | -484.15 | |
| Earnings yield | 0 | 0 | 0 | -0.01 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.12 | 0.04 | 0.04 | 0.05 | 0.05 | |
| Debt to assets | 0.1 | 0.04 | 0.04 | 0.04 | 0.04 | |
| Net debt to EBITDA | 0.07 | 0.15 | -0.87 | 10.1 | 3.81 | |
| Current ratio | 44.71 | 44.57 | 45.09 | 39.47 | 42.03 | |
| Interest coverage | 334.33 | 376.66 | 245.64 | -571.01 | -237.6 | |
| Income quality | -0.33 | -0.46 | -0.63 | 0.58 | 0.72 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.43 | 0.03 | 2.51 | 1.48 | 1.64 | |
| Research and developement to revenue | 9.54 | 0.2 | 18.86 | 17.77 | 9.59 | |
| Intangibles to total assets | 0.15 | 0.15 | 0.13 | 0.13 | 0.13 | |
| Capex to operating cash flow | 0.19 | 0.1 | 0.02 | 0.1 | 0.1 | |
| Capex to revenue | -1.24 | -0.02 | -0.29 | -2.67 | -0.9 | |
| Capex to depreciation | -0.51 | -0.09 | -0.04 | -0.34 | -0.18 | |
| Stock based compensation to revenue | 0.19 | 0 | 0.51 | 0.38 | 0.36 | |
| Graham number | 28.86 | 26.87 | 25.15 | 37.67 | 24.11 | |
| ROIC | 0.03 | 0.02 | 0.02 | -0.15 | -0.02 | |
| Return on tangible assets | 0.03 | 0.03 | 0.02 | -0.05 | -0.02 | |
| Graham Net | 15.67 | 18.01 | 20.28 | 19.07 | 19.39 | |
| Working capital | 7.73B | 7.56B | 8.44B | 8.02B | 8.19B | |
| Tangible asset value | 11.81B | 12.19B | 13.45B | 12.78B | 12.96B | |
| Net current asset value | 6.25B | 7.1B | 7.98B | 7.53B | 7.7B | |
| Invested capital | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.21M | 657K | 751K | 1.14M | 2.16M | |
| Average inventory | 96.87M | 96.39M | 104.56M | 113.24M | 117.99M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 4.61 | 0.3 | 8.79 | 11.47 | 22.58 | |
| Days of inventory on hand | 648.52 | 46.33 | 1.13K | 926.08 | 949.59 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 19.53 | 297.65 | 10.24 | 7.85 | 3.99 | |
| Inventory turnover | 0.14 | 1.94 | 0.08 | 0.1 | 0.09 | |
| ROE | 0.03 | 0.02 | 0.02 | -0.04 | -0.02 | |
| Capex per share | -0.06 | -0.05 | -0.01 | -0.1 | -0.05 |
4743.TWO Frequently Asked Questions
What is Oneness Biotech Co., Ltd. stock symbol ?
Oneness Biotech Co., Ltd. is a TW stock and trading under the symbol 4743.TWO
What is Oneness Biotech Co., Ltd. stock quote today ?
Oneness Biotech Co., Ltd. stock price is $233.5 today.
Is Oneness Biotech Co., Ltd. stock public?
Yes, Oneness Biotech Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 4.44M
- Market Capitalization 93.62B
- CEO Ms. Chih-Hui Cheng
- Headquarters Taipei,TW
- IPO Date 2011-09-23
-
Website
https://www.onenessbio.com.tw 
Oneness Biotech Co., Ltd engages in the research and development of new drugs, and sale of pharmaceutical and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis and systemic sclerosis; FB825, which is in Phase II clinical trial for treating atopic dermatitis, allergic diseases, and asthma; and FB918, a human monoclonal antibody, which is in pre-clinical stage for the treatment of allergic asthma. In addition, the company engages in the management of agriculture cultivation and trading business; and sale of agricultural products. The company was incorporated in 2008 and is headquartered in Taipei City, Taiwan.
